(NASDAQ: LGND) Ligand Pharmaceuticals's forecast annual revenue growth rate of 15.67% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 57.37%, and while it is forecast to beat the US market's average forecast revenue growth rate of 9.64%.
Ligand Pharmaceuticals's revenue in 2025 is $181,488,000.On average, 4 Wall Street analysts forecast LGND's revenue for 2025 to be $3,717,735,349, with the lowest LGND revenue forecast at $3,627,496,526, and the highest LGND revenue forecast at $3,793,233,429. On average, 4 Wall Street analysts forecast LGND's revenue for 2026 to be $4,455,988,100, with the lowest LGND revenue forecast at $4,160,594,388, and the highest LGND revenue forecast at $4,690,412,241.
In 2027, LGND is forecast to generate $5,478,501,827 in revenue, with the lowest revenue forecast at $5,153,472,273 and the highest revenue forecast at $5,902,085,991.